AI-powered imaging software begins market pilot


Tuesday, 21 September, 2021

AI-powered imaging software begins market pilot

Australian AI healthcare company Artrya’s non-invasive diagnostic support solution to detect coronary artery disease, Salix, has commenced its first market pilot with Perth-based radiology practice Envision Medical Imaging.

Developed through a collaboration with the The University of Western Australia, the Harry Perkins Institute of Medical Research and the Ottawa Heart Institute, the solution analyses cardiac CT scans using AI algorithms, producing a 3D image and report that provides disease detection.

Salix detects and assesses atherosclerotic plaque in a patient’s arteries, the substrate of most heart attacks, and is testing algorithms to further define the most vulnerable plaques.

Envision cardiologist Dr Lawrence Dembo said, “From the time a scan is completed, within a few minutes I can select the patient of highest interest, and all the vessels are tracked, lesions are identified and assessed, the calcium score is calculated and a report is written. All before I touch the keyboard.”

The solution can automatically assess Vulnerable Plaque, Stenosis, Calcium Score and total plaque burden, from a single scan at the point of care, in around 15 minutes. It is said to provide a detailed and accurate analysis of key CAD biomarkers from one CT scan.

Artrya Chief Medical Officer Professor Dwivedi said Salix unlocks the capability to triage patients into risk categories, identifying those patients who require further clinical assessments and those who can be reassured.

Artrya is planning an unrestricted launch across Australia for early 2022, with options for trial potentially sooner. The company intends to expand into targeted international markets in 2022, once international regulatory approvals have been acquired.

Image credit: ©stock.adobe.com/au/7activestudio

Related News

Booster shots to start in November; home-use tests to be available soon

The Therapeutic Goods Administration (TGA) has provisionally approved a booster dose of the...

Genetic risk test predicts alcohol-related cirrhosis

Cirrhosis (scarring of the liver) is responsible for approximately 300,000 deaths each year.

Encephalitis Information Week begins

Encephalitis Society has launched the inaugural Australian Encephalitis Information Week to...


  • All content Copyright © 2021 Westwick-Farrow Pty Ltd